Laser Treatment Policy
Pursuant to federal law 21 CFR 812.2(c)7 and 812.3(b), physician(s) at
this pain center may advise and use unapproved laser treatments on
patients under one or more of the following conditions:
1. A pain condition that has consistently failed to improve with
approved modalities of pain treatments.
2. Approved pain treatments are contraindicated, have caused or
intend to cause adverse effects specific to individual patients.
3. Drugs or drug based injection treatments are contraindicated to
an allergic reaction specific to individual patients.
4. Drug based injections may exceed safe dosage standards or may
result in adverse effects due to a pain condition requiring
treatments to multiple areas or require frequent repetitive
treatments.
5. Patient’s best interests are served by an individualized and
customized plan of pain treatment formulated by the treating
pain physician.
Low Intensity Laser Ablation
Painless Ablation Of Pain Nerves Produces
Long Lasting Pain Relief
Minimally invasive first in the world non heat producing laser. Selectively targets pain nerves without damaging healthy tissues by a process called LILA™ or Low Intensity Laser Ablation.
Surgery and pain medications can be avoided
with long lasting
pain relief.
The first patient treated in December 2009 is still back pain free. Non cancer bone and joint pain including back pain responds toLILA™.
Narcotics and similar pain medications are no longer
required to manage pain symptoms after treatment
.Multiple areas and whole body can be treated at the same time within a few minutes. Get total pain relief in one go!
Invented by Dr. Srini, LILA™ is NOT FDA approved and is available only at Advanced Interventional Pain Center pursuant to federal law 21 CFR 812.2(c)7 and 812.3(b). Patients are selected carefully on a case by case basis. Patients shall bear nominal charges for treatments and contribute towards data collection and research needed for FDA submission.
Individual results will vary
. About 100 patients including 10 police officers have been treated with excellent results.Injured workers can expect to
get the maximum benefit with these novel laser treatments.
Immediate Resolution Of Pain Symptoms
Immediate Improvement In Function
Long Lasting Pain Relief
No Drugs, No Anesthetics, No Adverse Effects
For More Info
Call 310-601-7635
Or Visit: www.inter-pain.com
Advanced
Interventional
Pain Center
Precise Diagnosis*Better Outcomes
11645 Wilshire Boulevard, Suite 852
Los Angeles, CA 90025
The Future of Pain Care is Here!
DT-LILT™ and LILA® are pending FDA approval
Deep Tissue Low Intensity Laser Therapy
(DT-LILT™)
is a minimally invasive novel technology using Low Intensity Laser Ablation (LILA®) for selectively destroying C pain fibers that are responsible for chronic pain symptoms. A variety of pain conditions that involve C fiber pain transmission can be treated resulting in instantaneous pain relief. Such pain relief is alsosustained over several months. DT-LILT™ indicates the group of medical applications collectively developed for using LILA®.
Low Intensity Laser Ablation (LILA®)
works by employing the phenomenon of cell absorption and selfdestruction to selectively destroy C pain fibers using a low intensity laser. Heat is not generated in the process preserving the integrity of healthy tissues and other types of nerve fibers . LILA® is easy to use, when one or more focal pain conditions exist and are confirmed by a physician’s clinical exam and diagnosis.
LILA® and DT-LILT™ are new concepts invented by Dr. Srinivasan, Clinical Director of Advanced Interventional Pain Center. LILA® and LILA® are in early clinical testing. They offer enormous advantage over all existing modalities of pain treatments for focal pain conditions. LILA® does not require any drugs and no sedation is required for the procedure. LILA® is devoid of adverse
effects when used appropriately and for this reason can be safely performed in a physician’s office. Learning LILA® and how to apply LILA® are easy, as the LILA® device is extremely user friendly. Interventional pain physicians should readily be able to use the treatments in their office with very little training.
Table 1. Shows the pain conditions that respond to
LILA®. Both instantaneous and sustained pain relief are obtained after LILA® in these pain
conditions. LILA® is able to provide pain relief in the focal pain area within a few seconds. Due to lack of adverse effects, multiple areas of pain in one patient can be treated at the same time within a few minutes.
The LILA® device is extremely user friendly. Interventional pain physicians should readily be able to use DT-LILT™ in their office with very little training.
DT-LILT™ is devoid of adverse effects when used
appropriately and for this reason can be safely performed in a physician’s office.
DT-LILT™ and LILA® are pending FDA approval
Table 1.
Pain Condition
Treated Area of Laser Anatomical Application Neuroablation of C Fibers of nerve or nerve branch DRE % Relief from Chronic Pain at 8 weeks* Post procedure tactile, sensory, motor functions Facet Joint
Arthritis Facet Joints (any level) Medial branch nerves 100% in the 1
st
treatment No change
Sacro-iliac
Arthritis Sacro-iliac joints L5, S1, S2 100% in the 1
st
treatment No change
Occipital
Headache Sub-Occipital Area of Cranium Occipital Nerve, (C-2) 95% in the 1
st
treatment, 100% after the 2nd
No change
Shoulder DJD Shoulder Joints Supra-scapular
nerve, (C-4) 100% in the 1
st
treatment No change
Knee DJD Knee Joints Femoral, tibial
and peroneal (L4, L5)
100% in the 1st
treatment No change
Elbow DJD Elbow Joints Peripheral
Branch of Median nerve
100% in the 1st
treatment No Change
Wrist DJD Wrist Joints Peripheral
Branch of Radial Nerve
100% in the 1st
treatment No change
Trochanteric
Bursitis Greater trochanter S1, L5, L4 100% in the 1
st treatment No change Rheumatic disorders affecting skin with excruciating pain symptoms
Skin All dermatomes 50% relief with
the 1st treatment,
85% relief at 4 weeks after the 2nd treatment No change Rheumatic Disorder affecting large joints Lumbar facets, SI joints and greater trochanter Lumbar medial branch nerves, sacral para-vertebral nerves (L4, L5, S1, S2) 70% relief after the 1st treatment. 100% relief after 2nd, 4 weeks later at follow up No change
*Diagnosis related estimated pain relief
Instantaneous pain relief with LILA® has been
observed in hip and ankle pain after LILA® treatments. Single session whole body treatment in multi-joint pain symptoms has also shown to provide both
instantaneous and long term pain relief.
Rheumatic pain conditions: LILA® can effectively reduce pain symptoms of large joints and does not interfere with immunosuppressive treatments which can be administered concurrently with LILA®. Rheumatic patients vary in response to LILA®. LILA® has been beneficial in SLE related pain symptoms where the RF (rheumatic factor) has been normal. Pain treatments in personnel of armed forces, law enforcement, operators of public transport and heavy machinery : LILA® should be the first choice of treatment in this group being a drugless pain treatment modality, avoiding sedation and drowsiness.
Instantaneous and sustained pain relief can be obtained with LILA® where indicated resulting in early return to work.
The Future of Pain Care is Here!
DT-LILT™ and LILA® are pending FDA approval
Theoretical Considerations where LILA® may be effective are listed below. Physician researchers interested in using LILA® for the following should contact Dr. Srinivasan at 765-891-0721 for further information.
1. Sympathetically mediated pain in cancer pain (not tested) : LILA® can be employed for prolonged pain relief through C fiber destruction in the thoracic area. We expect LILA® to be effective in non metastatic abdominal pain from pancreatic cancer either individually or as an adjunct therapy. These procedures are in development. C pain fiber destruction in the
sympathetic trunk is not advisable in non cancer pain using LILA®.
2. Temporomandibular Joint Disorder (TMJ) (not tested): LILA® can effectively treat TMJ. The procedure is being developed. The facial nerve runs in close proximity to TMJ, for this reason physicians intending to treat TMJ should not use LILA® until research results are available. 3. Pediatric pain (not tested): LILA® should effectively address C fiber pain transmission during
trauma pain by both reducing the sensitivity and intensity of trauma pain in the pediatric population. Procedures are yet to be developed. Research enquiries are welcome. Special Considerations: LILA® can provide pain relief where other treatments have failed or are providing only partial pain relief:
1. Failed back surgery syndrome (FBSS) : Complete resolution of back pain symptoms can be obtained in cases of FBSS with or without posterior fixation rods when facet joints are the cause of pain. About 20 seconds of LILA® can provide instantaneous pain relief at L4 and L5 levels in a single treatment, pain relief is sustained over several months.
2. Failed or partial spinal cord stimulation: LILA® can augment pain relief when an implanted spinal cord stimulator has failed or is providing only partial pain relief. Spinal cord stimulation should be stopped during LILA® and can be
resumed after the treatment if needed. 3. Failed or partially effective intrathecal drug
pumps: LILA® can augment pain relief when an implanted intrathecal drug pump has failed or is providing only partial pain relief. LILA® can be applied without stopping the intrathecal pump. Care must be taken not to introduce the laser needle
into the intrathecal catheter. Intra-operative fluoroscopy is a must for all spinal procedures involving LILA®.
Absolute Contraindication for LILA®: LILA® should not be used to treat radicular pain symptoms which are characterized by sharp shooting, non-localizing, radiating pain symptoms as a result of A-delta pain transmission. The origin of radicular pain is at the spinal neuroforamen or within the spinal canal and these areas are an absolute contraindication for LILA®.
Relative contraindications for LILA®: LILA® should not be applied in the axilla, cubital tunnel, carpal tunnel, or laterally over the digital nerves. Hip joints are relatively contraindicated using the posterior
The origin of radicular pain is at the spinal neuroforamen or within the spinal canal and these areas are an absolute contraindication for LILA®.
DT-LILT™ and LILA® are pending FDA approval
approach due to the sciatic nerve overlying the hip joints in this area. Other relatively contraindicated areas include the popliteal fossa, tarsal tunnel and digital nerves of the foot.
About 100 PATIENTS INCLUDING 10 POLICE OFFICERS HAVE BEEN TREATED WITH LILA® WITH OUTSTANDING PAIN RELIEF AND SUSTAINED IMPROVEMENT IN FUNCTION. THERE ARE NO ADVERSE EFFECTS ASSOCIATED WITH LILA®
For Enquiries in US, contact: Pattanam Srinivasan, M.D. Clinical Director
Advanced Interventional Pain Center Tel: 765-891-0721
E-mail: srinidoc@inter-pain.com www.inter-pain.com
LILA® laser treatments are NOT FDA approved and are available only at Advanced Interventional Pain Center consistent with federal law 21 CFR 812.2(c)7 and 812.3(b)